Nevertheless, the SelectMDx® score has been shown to enable objective clinical risk assessment and patient management by remaining the strongest, most significant predictor of patient risk compared with other clinically relevant risk assessment algorithms, such as prostate cancer antigen 3 and the Prostate Cancer Prevention Trial risk calculator [9]. This evidence concerns the gene PCA3 and prostate carcinoma.